Eucrates Biomedical Acquisition Corp.
EUCR · NASDAQ
12/31/2022 | 9/30/2022 | 6/30/2022 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | $30 | $105 | $104 | $29 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $30 | $105 | $104 | $29 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$0 | -$1 | -$1 | -$1 |
| % Margin | – | – | – | – |
| Net Income | $1 | $1 | $1 | $3 |
| % Margin | – | – | – | – |
| EPS Diluted | 0.18 | 0.09 | 0.067 | 0.21 |
| % Growth | 100.2% | 33.6% | -68% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |